XFOR

X4 Pharmaceuticals Inc

3.36

Oct 29 • 3:59 PM ET +0.01 (0.30%)

3.32

Aftermarket • 7:30 PM ET -0.04 (-1.19%)

Healthcare Biotechnology USA Small NASD

Oct 29, 4:36 PMX4 Pharmaceuticals sees 15,000–30,000 U.S. patient opportunity for mavorixafor in primary chronic neutropenia

Peers: PHAR ZVRA ADMA RIGL RARE PLX RLYB MIRM KRYS CTXR

| Held by: VTI IWM IWN VXF VTWO IWC SBIO AVSC VTWV PRFZ

Scroll to Statements

Index	RUT
Market Cap	333.13M
Enterprise Value	201.80M
Income	-90.14M
Sales	15.85M
Book/sh	1.62
Cash/sh	2.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	45
IPO	Nov 16, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	21.02
P/B	2.08
P/C	1.60
P/FCF	-
EV/EBITDA	-
EV/Sales	12.73
Quick Ratio	11.02
Current Ratio	11.30
Debt/Eq	0.50
LT Debt/Eq	0.49
Option/Short	Yes / Yes

EPS (ttm)	-1.19
EPS next Y	-0.70
EPS next Q	-0.18
EPS this Y	65.13%
EPS next Y	-7.98%
EPS next 5Y	23.57%
EPS past 3/5Y	65.48% 54.19%
Sales past 3/5Y	- 63.56%
EPS Y/Y TTM	91.93%
Sales Y/Y TTM	-51.65%
EPS Q/Q	96.32%
Sales Q/Q	346.33%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	26.14% 263.88%

Insider Own	24.29%
Insider Trans	-0.43%
Inst Own	79.53%
Inst Trans	3.23%
ROA	-50.32%
ROE	-113.08%
ROIC	-38.82%
Gross Margin	80.77%
Oper. Margin	-554.71%
Profit Margin	-568.80%
SMA20	14.79%
SMA50	0.59%
SMA200	-11.65%
Trades

Shs Outstand	96.11M
Shs Float	75.06M
Short Float	9.98%
Short Ratio	8.83
Short Interest	7.49M
52W High	4.83 -30.43%
52W Low	2.43 38.27%
Volatility	8.47% 7.34%
ATR (14)	0.23
RSI (14)	60.87
Beta	0.51
Rel Volume	1.07
Avg Volume	848.28K
Volume	911,233

Perf Week	5.00%
Perf Month	15.86%
Perf Quarter	-15.58%
Perf Half Y	-17.44%
Perf YTD	-16.00%
Perf Year	-10.16%
Perf 3Y	-84.18%
Perf 5Y	-97.69%
Perf 10Y	-
Recom	1.00
Target Price	11.60
Prev Close	3.35
Price	3.36
Change %	0.30%

Consensus

Strong Buy

Avg. Price Target

$11.60

Implied Upside

+245.2%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 10, 2026	Initiated	WWells Fargo	Overweight	$11	+227.4%
Jun 02, 2026	Initiated	LLeerink Partners	Outperform	$12	+257.1%
Mar 09, 2026	Initiated	GGuggenheim	Buy	$12	+257.1%
Dec 05, 2025	Resumed	SStifel	Buy	$10	+197.6%
Dec 12, 2023	Downgrade	RB. Riley Securities	Buy → Neutral	$3 → $1	-70.2%
Aug 30, 2023	Resumed	RB. Riley Securities	Buy	$3	-10.7%
Dec 22, 2022	Initiated	CCantor Fitzgerald	Overweight	$3	-10.7%
Dec 12, 2022	Initiated	PPiper Sandler	Overweight	$3	-10.7%
Dec 23, 2019	Initiated	OOppenheimer	Outperform	$20	+495.2%
Dec 18, 2019	Initiated	RROTH Capital	Buy	$20	+495.2%
Dec 09, 2019	Upgrade	CCitigroup	Neutral → Buy	$16 → $20	+495.2%
Dec 05, 2019	Initiated	BB. Riley FBR	Buy
Jun 07, 2019	Initiated	SStifel	Buy	$27	+703.6%
Jun 05, 2019	Initiated	CCowen	Outperform

Oct-29-26 04:30PM	X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day (GlobeNewswire)
Oct-09-26 07:00AM	X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders (GlobeNewswire)
Oct-08-26 08:30AM	X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures (InvestorsHub)
07:00AM	X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures (GlobeNewswire)
Oct-01-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Loading…
Sep-09-26 07:00AM	X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference (GlobeNewswire)
Sep-08-26 07:00AM	X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting (GlobeNewswire) -13.24%
Sep-01-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 05:22PM	X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press) +11.27%
04:15PM	X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-07-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-26 07:00AM	X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors (GlobeNewswire) -12.53%
Jun-01-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 07:00AM	X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
07:26AM	Loading…
May-06-26 07:26AM	X4 Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
07:15AM	X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-26 07:00AM	X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union (GlobeNewswire)
Apr-01-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.33%
Mar-17-26 07:34AM	X4 Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance) +18.82%
07:15AM	X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 11:15AM	X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention (24/7 Wall St.) +10.37%
Mar-04-26 07:00AM	X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference (GlobeNewswire) +5.11%
Mar-02-26 04:30PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-26 07:00AM	X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome (GlobeNewswire) +5.85%
Feb-26-26 12:15PM	Vericel Corporation (VCEL) Matches Q4 Earnings Estimates (Zacks) -5.52%
Feb-16-26 03:04AM	X4 Pharmaceuticals Details Mavorixafor Phase 3 Push, Cost Cuts and Chronic Neutropenia Market Plan (MarketBeat)
Feb-03-26 07:00AM	X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-02-26 04:01PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.57%
Jan-12-26 12:00PM	All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy (Zacks)
09:55AM	Loading…
Dec-24-25 09:55AM	Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? (Zacks) +7.28%
Nov-05-25 04:01PM	X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference (GlobeNewswire) -10.58%
10:00AM	MeiraGTx Holdings PLC (MGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
08:15AM	X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:40AM	Techne (TECH) Meets Q1 Earnings Estimates (Zacks)
07:22AM	X4 Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-27-25 07:05PM	X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million (GlobeNewswire)
Oct-24-25 12:37AM	X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering (GlobeNewswire) +22.98%
Oct-23-25 04:01PM	X4 Pharmaceuticals Announces Proposed Underwritten Public Offering (GlobeNewswire)
Oct-22-25 12:00PM	X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Sep-17-25 07:00AM	X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation (GlobeNewswire) -5.30%
Aug-15-25 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.24% -12.63%
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +13.57%
07:00AM	X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement (GlobeNewswire)
Aug-12-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +81.69%
07:00AM	X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership (GlobeNewswire)
Aug-08-25 05:13PM	X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
Jun-16-25 08:00AM	X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) (GlobeNewswire)
Jun-10-25 08:00AM	X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA (GlobeNewswire) -14.01%
Jun-02-25 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +12.06%
May-14-25 04:12PM	X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress (GlobeNewswire) -6.79%
May-02-25 03:06AM	X4 Pharmaceuticals Inc (XFOR) Q1 2025 Earnings Call Highlights: Progress in Maverick 4 ... (GuruFocus.com)
May-01-25 12:44PM	X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript (Seeking Alpha) -12.99%
06:11AM	X4 Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
06:01AM	X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-30-25 06:03AM	Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025 (Insider Monkey)
Apr-24-25 08:03AM	X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025 (GlobeNewswire) -7.00%
08:00AM	X4 Pharmaceuticals Announces Reverse Stock Split (GlobeNewswire)
Apr-23-25 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-26-25 03:01AM	X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com)
12:31AM	Q4 2024 X4 Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-25-25 03:02PM	X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript (SeekingAlpha) -12.07%
06:18AM	X4 Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
06:01AM	X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-25 09:05AM	X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Mar-11-25 08:00AM	X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025 (GlobeNewswire)
Feb-20-25 10:22AM	X4 and taiba to distribute WHIM syndrome therapy in Middle East (Pharmaceutical Technology) -6.05%
Feb-19-25 07:35AM	X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI (mavorixafor) in WHIM Syndrome in Select Middle East Countries (GlobeNewswire)
Feb-07-25 05:52AM	Bain buys Mitsubishi pharma unit; Bausch + Lomb deal talks come up empty (BioPharma Dive)
Feb-06-25 07:35AM	X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia (GlobeNewswire) -10.83%
Feb-03-25 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.28%
Jan-24-25 07:36AM	X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome (GlobeNewswire) -7.78%
Jan-13-25 07:35AM	X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand (GlobeNewswire)
Dec-04-24 08:00AM	X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting and Exposition (GlobeNewswire)
08:00AM	X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting & Exposition (GlobeNewswire)
Dec-03-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 08:00AM	X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-14-24 08:00AM	X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference (GlobeNewswire) +47.85%
02:06AM	X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... (GuruFocus.com)
Nov-13-24 06:26AM	X4 Pharmaceuticals Posts Wider Loss In Q3 - Quick Facts (RTT News) -53.17%
06:13AM	X4 Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:07AM	X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
06:01AM	X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) (GlobeNewswire)
Nov-07-24 11:36AM	The people-first approach transforming eClinical processes (Clinical Trials Arena) +6.53%
Nov-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-24-24 08:00AM	X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024 (GlobeNewswire)
Oct-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.09%
Sep-03-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.80%
Aug-28-24 08:00AM	X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-24 06:13AM	X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
06:01AM	X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-01-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.16%
Jul-30-24 08:00AM	X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024 (GlobeNewswire)
Jun-27-24 06:30AM	X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial (GlobeNewswire) -32.99%
Jun-03-24 04:05PM	X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
May-29-24 04:30PM	X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia (GlobeNewswire)
May-13-24 08:00AM	X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire) -6.99%
May-09-24 03:59PM	Sector Update: Health Care Stocks Higher Late Afternoon (MT Newswires)
11:52AM	X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise (MT Newswires)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Craig Adam R	Executive Chairman	Oct 16 '26	Buy	2.58	4,600	11,884	333,251	Oct 19 04:06 PM
KIRSKE DAVID	Chief Financial Officer	Oct 01 '26	Sale	2.86	11,767	33,658	155,983	Oct 05 04:03 PM
David Kirske	Officer	Oct 01 '26	Proposed Sale	2.86	11,767	33,658		Oct 01 08:05 PM
Volpone John	President	Aug 12 '26	Sale	4.44	24,576	109,228	265,305	Aug 13 04:13 PM
Craig Adam R	Executive Chairman	Aug 12 '26	Sale	4.44	47,436	210,829	328,651	Aug 13 04:10 PM
John Volpone	Officer	Aug 12 '26	Proposed Sale	4.55	24,576	111,944		Aug 13 04:00 PM
Adam Craig	Executive Chaiman	Aug 12 '26	Proposed Sale	4.56	47,436	216,071		Aug 13 03:59 PM
KIRSKE DAVID	Chief Financial Officer	Jun 30 '26	Sale	4.26	8,543	36,428	167,750	Jul 01 04:23 PM
KIRSKE DAVID	Chief Financial Officer	May 12 '26	Sale	4.29	16,961	72,820	176,293	May 13 04:02 PM
David Kirske	Officer	May 12 '26	Proposed Sale	4.29	16,961	72,820		May 12 06:11 PM

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

M.D.Dr. Adam R. Craig M.B.A.

President & COOMr. John P. Volpone M.B.A.

CFOMr. David H. Kirske

Ph.D.Dr. Richard Peters M.D.

FounderDr. Renato T. Skerlj Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XFOR

X4 Pharmaceuticals Inc

Upgrade your Finviz experience